Blood-based cardiometabolic phenotypes in atrial fibrillation and their associated risk: EAST-AFNET 4 biomolecule study
Larissa Fabritz(University of Birmingham), Paulus Kirchhof(University of Birmingham), Shinwan Kany(University Hospital Frankfurt), Christina Magnussen(German Centre for Cardiovascular Research), Andreas Goette(Otto-von-Guericke University Magdeburg), Linda Krause(Universität Hamburg), Günter Breithardt(University Hospital Münster), Katrin Borof(Universität Hamburg), Tanja Zeller(German Centre for Cardiovascular Research), Ulrich Schotten(Maastricht University), Karl Wegscheider(Universität Hamburg), Antonia Zapf(Universität Hamburg), Patrick T. Ellinor(Massachusetts General Hospital), Victor Roth Cardoso(University of Birmingham), Winnie Chua(University of Birmingham), Ursula‐Henrike Wienhues‐Thelen(Roche (Switzerland)), Georgios V. Gkoutos(University of Cambridge), Renate B. Schnabel(University Medical Center Hamburg-Eppendorf), Harry J.G.M. Crijns, Anna Suling(Universität Hamburg), Christoph Al-Taie(Universität Hamburg), A. John Camm(St George's, University of London)
Cited by 20
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|EP Europace|2016|6.5k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|European Heart Journal|2016|6.4k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k